UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point

Quick Read

• Jazz Pharmaceuticals (JAZZ) received a Buy upgrade from UBS with a $307 price target, reflecting confidence in the company’s $1.07B Q1 2026 revenue (up 19% YoY) with adjusted EPS of $6.34 beating consensus estimates.

• UBS’s upgrade signals that Jazz Pharmaceuticals’ fundamentals, pipeline catalysts, and valuation are converging at an inflection point the market hasn’t yet fully priced in.

• The analyst who called NVIDIA in 2010 just named his top 10 stocks and Jazz Pharmaceuticals wasn't one of them. Get them here FREE.

One of Wall Street's major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying. UBS upgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy with a $307 price target, signaling the firm sees a constructive setup the market hasn't yet priced. For long-term investors, the call lands at a moment when fundamentals, pipeline catalysts, and valuation appear to be converging.

Jazz Pharma stock has already run hard into the upgrade, climbing 39% year to date (YTD) and 116% over the past year. The UBS target sits well above the current consensus of $241.76, suggesting the firm sees room for further repricing.

The Analyst's Case

The UBS upgrade likely centers on a perceived inflection in Jazz Pharmaceuticals' fundamentals. Oxybate franchise resilience, Epidiolex growth in epilepsy, oncology pipeline progression, and an attractive valuation relative to specialty pharma peers form the bull thesis.

The analyst who called NVIDIA in 2010 just named his top 10 stocks and Jazz Pharmaceuticals wasn't one of them. Get them here FREE.

Recent results back that view. Jazz Pharmaceuticals delivered $1.07 billion in Q1 2026 revenue, a 19% year over year (YoY) gain, with adjusted EPS of $6.34 trouncing the $4.66 consensus. The oncology portfolio grew 45%, reinforcing the company's pivot narrative.

Company Snapshot

Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience and oncology, with key products including Xywav (sleep), Epidiolex (epilepsy), and Rylaze (oncology). The Dublin-based firm carries a market capitalization of $14.4 billion.

Xywav, Jazz Pharma's lead sleep franchise, posted $408.2 million in Q1 sales, up 18%, while Epidiolex contributed $249.8 million, up 15%. Zepzelca surged 60% to $101 million on its first-line small cell lung cancer combination.

Why the Move Matters Now

The price target raise from UBS arrives ahead of a pivotal catalyst: the August 25 PDUFA date for zanidatamab in first-line HER2-positive gastroesophageal cancer. Analysts project peak sales potential of over $2 billion for the asset.